RxDoctor Payments Data

Nooreen Baig, MD

Internal Medicine · Houston, TXNPI 1619387057

Payments from drug & device makers

$6,757in general payments, 2019–2025

Across 353 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$665
  • Pfizer$519
  • GSK$433
  • Lilly USA, LLC$385
  • Amgen$350
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$6,757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,757 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,303
Medicare patients
161
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$73,632
JardianceEmpagliflozin36$51,790
FarxigaDapagliflozin Propanediol19$24,497
EliquisApixaban23$22,422
MounjaroTirzepatide23$21,974
JanuviaSitagliptin Phosphate11$12,683
MyrbetriqMirabegron19$11,647
TradjentaLinagliptin13$8,605
Atorvastatin Calcium297$3,589
Icosapent Ethyl11$3,444
Rosuvastatin Calcium109$2,864
Levothyroxine Sodium125$2,344
Losartan Potassium133$1,875
Valsartan28$1,775
Gabapentin83$1,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$665$73,63269 claims
Boehringer IngelheimJardiance, Tradjenta$147$60,39449 claims
AstraZenecaFarxiga$175$24,49719 claims
PfizerEliquis$519$22,42223 claims
Lilly USA, LLCMounjaro$385$21,97423 claims
MerckJanuvia$14$12,68311 claims
AbbVieSynthroid$1,114$1,41620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →